M1FG
ARQT icon

Mach-1 Financial Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Mach-1 Financial Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,254
Closed -$312K – 257
2025
Q2 		$312K Buy
+22,254
New +$312K 0.09% 202

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mach-1 Financial Group's ARQT Position: Q3 2025 in Review

Mach-1 Financial Group sold out of Arcutis Biotherapeutics (ARQT) in Q3 2025, closing a stake of 22,254 shares — an estimated $312K sold.

Mach-1 Financial Group first reported a position in ARQT in Q2 2025 and held it in 1 quarter. The position peaked at $312K in Q2 2025. 239 funds tracked by Wall St. Rank hold ARQT as of Q3 2025.

  • Mach-1 Financial Group reported no remaining Arcutis Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 22,254 Arcutis Biotherapeutics shares in Q3 2025, an estimated $312K.
  • Mach-1 Financial Group first reported a position in Arcutis Biotherapeutics in Q2 2025 and held it in 1 quarter.
  • Mach-1 Financial Group's Arcutis Biotherapeutics position peaked at $312K in Q2 2025.
  • 239 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2025.

Based on Mach-1 Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.